Mesoblast (MEOBF) Stock Price, News & Analysis

Company Overview

Mesoblast Limited is a biotechnology company focused on developing cellular medicines for serious inflammatory and immune-mediated diseases. The company’s therapies are based primarily on its proprietary mesenchymal lineage stromal cell technology, which is designed to regulate excessive immune responses and inflammation and support tissue repair.

Mesoblast’s lead product, Ryoncil (remestemcel-L), is an allogeneic mesenchymal stromal cell therapy approved in the United States for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients two months of age and older. The company has also developed investigational cell therapies for conditions including chronic heart failure, chronic low back pain, and other disorders involving inflammation or tissue damage.

Founded in Australia, Mesoblast operates internationally, with research, clinical development, and commercial activities spanning Australia, the United States, and other markets. The company was founded by Silviu Itescu, who serves as chief executive officer and has led its development of cell-based therapies.

Key Stats

• Today's Range: $1.90 to $1.90
• 50-Day Range: $1.65 to $1.90
• 52-Week Range: $1.30 to $2.59
• Volume: N/A
• Average Volume: 73,011 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:MEOBF
• CIK: 1345099
• Web: www.mesoblast.com
• Phone: (139) 639-6036
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A